The Green Endoscopy Unit (GIE) concept, set to launch in January 2026, aims to minimize the environmental impact of endoscopic procedures while maintaining high-quality patient care. Its core strategy revolves around reducing unnecessary activities, emphasizing high-value care with the lowest environmental cost.
The Green Endoscopy Unit (GIE) concept, set to launch in January 2026, aims to minimize the environmental impact of endoscopic procedures while maintaining high-quality patient care. Its core strategy revolves around reducing unnecessary activities, emphasizing high-value care with the lowest environmental cost. Adherence to evidence-based guidelines and structured triage systems ensures only clinically appropriate and timely procedures are performed, avoiding low-value or repeat interventions.
Key practices include provider education to improve referral quality, patient communication to explain deferred procedures, and the use of non-endoscopic alternatives when suitable. Efficient scheduling prevents cancellations and resource underutilization, while combining procedures into single visits reduces overall waste.
Operational strategies involve minimizing instrument use, simplifying interventions, avoiding low-yield biopsies, and consolidating specimens to reduce material consumption. Inventory management prevents overstocking and expiration, supported by first-in, first-out storage practices. Sedation methods and IV fluid use are optimized to match patient needs, avoiding excess resource use.
The unit also focuses on reducing paper dependency through digital documentation and encourages patient engagement by promoting reusable personal items. These measures collectively align with sustainability goals, ensuring environmentally conscious endoscopic care without compromising clinical outcomes. GIE represents a forward-thinking approach to healthcare delivery in the face of climate challenges.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.